Vivatides Therapeutics
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Vivatides Therapeutics - overview
Established
2025
Location
Hong Kong, -, Hong Kong SAR - China
Primary Industry
Healthcare
About
Founded in 2025 and based in Hongkong, Vivatides Therapeutics is a biotechnology company developing extra-hepatic targeted small-nucleic-acid therapeutics. In August 2025, the company raised USD 10000000 of Seed funding led by Apricot Capital and participation by Qiming Venture Partners.. Vivatides Therapeutics is developing a preclinical extra-hepatic targeted oligonucleotide delivery platform and associated therapeutic pipelines (including both ASO and siRNA approaches) aimed at enabling targeted delivery beyond the liver. Public descriptions emphasize platform differentiation at the design level to overcome extra-hepatic delivery challenges.
Vivatides generates revenue through partnering/licensing deals with larger biopharma companies (upfront payments, milestones, royalties), sponsored R&D or co-development agreements, and non-dilutive funding such as government grants or research contracts.
Current Investors
Qiming Venture Partners, Apricot Capital
Primary Industry
Healthcare
Sub Industries
Biotechnology, Healthcare
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.